Diagnosing and monitoring Monoclonal Gammopathy of Undetermined Significance (MGUS) can have an overwhelming impact on the outcomes of those who go on to develop myeloma. Ensuring an early myeloma diagnosis is critical to reducing the life-altering implications we see too often in those receiving a late diagnosis.

To support primary and secondary care professionals’ knowledge in Monitoring MGUS, Myeloma UK has launched a new, free interactive module, accredited by the Royal College of Physicians.

The course, which counts towards continued professional development (CPD), was developed with a panel of experts and offers HCPs a greater understanding of MGUS, and why it is important to diagnose the condition.

The resource includes videos featuring Dr Karthik Ramasamy and Dr Simon Stern, Consultant Haematologists and co-authors of the module, describing the significance of an MGUS diagnosis to a patient and offering insight into the risk stratification of the condition.

With a focus on the need and strategies for monitoring, this module is an excellent learning tool to ensure you feel confident in managing MGUS in practice. Discover our Monitoring MGUS module here on the NHS learning Hub, alongside our AL amyloidosis module.